Skip to main content

Table 3 Multivariate regression analyses of local and systemic reactions in the short-term survey and of outpatient and inpatient consultations reported in the long-term and follow-up surveys. Odds ratio of reporting local and systemic adverse events in the short-term survey (A) and consulting a doctor (outpatient consultation) or seeking hospital care (inpatient consultation) (both occurred and planned) in the long-term (B) and follow-up survey (C) depending on the vaccine used compared to comparator vaccines, age, sex, comorbidities and interval between vaccination and study registration

From: Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study

A

Short-term survey

Local reactions

Systematic reactions

n = 3262; reference = comparator vaccines

 

OR

95% CI

p-value

OR

95% CI

p-value

  

LL

UL

  

LL

UL

 

Intercept

1.81

1.20

2.74

0.005

0.94

0.61

1.43

0.765

BNT

1.52

1.11

2.09

0.009

1.82

1.31

2.54

0.0004

MOD

3.12

2.20

4.44

 < 0.0001

2.69

1.89

3.85

 < 0.0001

AZ

1.69

1.10

2.60

0.017

11.52

7.04

19.29

 < 0.0001

JAN

1.04

0.66

1.64

0.857

7.61

4.64

12.72

 < 0.0001

Age

0.97

0.97

0.98

 < 0.0001

0.97

0.97

0.98

 < 0.0001

Female

2.13

1.84

2.48

 < 0.0001

1.81

1.56

2.10

 < 0.0001

m-SCQ-D

1.05

1.00

1.10

0.065

1.18

1.12

1.24

 < 0.0001

Interval V-R

1.01

1.00

1.03

0.347

1.03

1.01

1.05

0.013

Another V

0.83

0.63

1.09

0.172

0.87

0.66

1.14

0.304

B

Long-term survey

Outpatient consultation

Inpatient consultation

n = 3374; reference = comparator vaccines

 

OR

95% CI

p-value

OR

95% CI

p-value

  

LL

UL

  

LL

UL

 

Intercept

0.14

0.08

0.23

 < 0.0001

0.04

0.01

0.14

 < 0.0001

BNT

0.87

0.61

1.25

0.436

0.54

0.25

1.26

0.128

MOD

0.98

0.66

1.49

0.936

0.52

0.20

1.41

0.190

AZ

1.42

0.84

2.48

0.183

1.14

0.33

3.52

0.829

JAN

1.43

0.81

2.48

0.208

0.74

0.16

2.73

0.675

Age

0.99

0.98

1.00

0.005

0.98

0.96

1.00

0.019

Female

1.58

1.28

1.96

 < 0.0001

1.29

0.76

2.25

0.354

m-SCQ-D

1.27

1.21

1.34

 < 0.0001

1.27

1.13

1.40

 < 0.0001

Interval V-R

1.01

1.00

1.01

0.170

1.01

0.99

1.03

0.173

Another V

0.85

0.65

1.09

0.206

0.84

0.42

1.58

0.602

C

Follow-up survey

Outpatient consultation

Inpatient consultation

n = 9978; reference = comparator vaccines

 

OR

95% CI

p-value

OR

95% CI

p-value

  

LL

UL

  

LL

UL

 

Intercept

0.17

0.12

0.25

 < 0.0001

0.02

0.01

0.04

 < 0.0001

BNT + BNT

0.84

0.63

1.13

0.239

0.97

0.48

2.19

0.943

MOD + MOD

0.88

0.65

1.21

0.441

0.92

0.43

2.18

0.847

AZ + AZ

0.52

0.35

0.76

0.001

0.52

0.20

1.40

0.186

AZ + BNT

0.57

0.41

0.79

0.001

0.34

0.14

0.86

0.018

AZ + MOD

0.47

0.33

0.67

0.0001

0.24

0.09

0.65

0.005

Age

1.00

0.99

1.00

0.056

0.99

0.99

1.00

0.277

Female

1.38

1.24

1.54

 < 0.0001

0.84

0.65

1.10

0.207

m-SCQ-D

1.26

1.22

1.29

 < 0.0001

1.21

1.15

1.28

 < 0.0001

Interval V-R

1.01

1.01

1.01

 < 0.0001

1.01

1.01

1.02

 < 0.0001

Another V

0.90

0.77

1.05

0.201

1.03

0.69

1.50

0.873

  1. BNT BNT162b2, MOD mRNA-1273, AZ ChAdOx1, JAN Ad26.COV2.S, OR odds ratio, 95% CI 95% confidence interval, LL lower limit, UL upper limit, Interval V-R interval between vaccination and study registration, Another V another vaccination in the 8 weeks prior to registration or since answering the last survey
  2. Reference vaccination: comparator vaccination; sex reference: male; age in years; m-SCQ-D: continuous variable
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us